+

WO1998001755A1 - Procede de criblage de proteines mena intervenant dans la dynamique des microfilaments - Google Patents

Procede de criblage de proteines mena intervenant dans la dynamique des microfilaments Download PDF

Info

Publication number
WO1998001755A1
WO1998001755A1 PCT/US1997/011669 US9711669W WO9801755A1 WO 1998001755 A1 WO1998001755 A1 WO 1998001755A1 US 9711669 W US9711669 W US 9711669W WO 9801755 A1 WO9801755 A1 WO 9801755A1
Authority
WO
WIPO (PCT)
Prior art keywords
mena
xaa xaa
pro
ser
ala
Prior art date
Application number
PCT/US1997/011669
Other languages
English (en)
Other versions
WO1998001755A9 (fr
Inventor
Frank B. Gertler
Philippe Soriano
Jurgen Wehland
Kirsten Niebuhr
Original Assignee
Fred Hutchinson Cancer Research Center
Gesellschaft Fur Biotechnologische Forshung Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Research Center, Gesellschaft Fur Biotechnologische Forshung Mbh filed Critical Fred Hutchinson Cancer Research Center
Publication of WO1998001755A1 publication Critical patent/WO1998001755A1/fr
Publication of WO1998001755A9 publication Critical patent/WO1998001755A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the invention relates to DNA sequences encoding proteins involved in microfilament dynamics. More specifically, the invention relates to DNA sequences and proteins involved in microfilament dynamics affecting normal and abnormal cell morphology, adhesion, motility, growth and differentiation, as well as pathogenicity of certain viruses and bacteria, and to screening, diagnostic and therapeutic methods and compositions employing these DNA sequences and proteins.
  • Actin-driven formation of membrane protrusions is the first step in migration of neurona! growth cones ( Forscher et al , Nature 357:, 515-8, 1992; Forscher and Smith, S., J. Cell Biol. 107: 1505-1516, 1988; Sanders and Wang, J. Cell Sci. 100:, 771-780, 1991).
  • Establishment of proper connections in the central nervous system depends on the ability of neuronal growth cones to guide neurites to their final targets. Genetic analyses have been used to probe the relationship between signal transduction pathways and neuronal development.
  • Abl mutants that are also heterozygous for a mutation in Disabled (Dab), or one of 4 other loci identified in genetic modifier screens require Abl tyrosine kinase activity for post-pupal viability and proper formation of the embryonic central nervous system (CNS). Animals that are homozygous mutant for both Abl and Dab make few or no proper axonal connections.
  • Dab Disabled
  • CNS embryonic central nervous system
  • Ena protein is concentrated in CNS axons, like Abl and Dab, and has a proline-rich core which binds in vitro to the SH3 domains of Abl and Src, but not to the SH3 domains of several other proteins tested (Gertler et al., Genes Dev. 9: 521-33, 1995).
  • Ena is tyrosine phosphorylated in vivo. The phosphotyrosine content of Ena is reduced approximately three-fold in Abl mutant pupae, indicating that Ena is phosphorylated by Abl- dependent and independent tyrosine kinases. Over expression and in vitro phosphorylation studies demonstrate that Abl can phosphorylate Ena directly.
  • Listeria motility and intercellular infection depends on the asymmetric recruitment of host profilin, an actin monomer binding protein, to one pole of the bacteria where rapid polymerization of actin is induced to form a microfilamentous "comet tail" that drives bacterial movement (Theriot et al., Cell 76: 505-517, 1994).
  • VASP Vasodilator-Stimulated Phosphoprotein
  • VASP is distributed along microfilaments, is particularly concentrated at sites of focal contact and in the peripheral lammelli of spreading or migrating cells, and there is evidence of direct contact between VASP and F-actin (Reinhard et al., EMBO J. 11: 2063-2070, 1992; Haffner et al., EMBO J. 14: 19-27, 1995).
  • VASP also contains a central region of proline-rich sequences comprising a proposed binding domain for the actin binding protein profilin (Reinhard et al., EMBO J. 14: 1583-1589, 1995).
  • VASP is recruited to the bacterial surface by direct binding with the ActA surface protein (Chakraborty et al., EMBO J.
  • VASP accumulates on the bacterial surface prior to the formation of F-actin clouds that precede comet tail formation, and is later localized at the site of actin filament assembly between the polar bacterial surface and the front of the actin tail (Chakraborty et al., EMBO J. J_4: 1314-1321, 1995). VASP is also a ligand for profilin (Reinhard et al., EMBO J. H: 1583-1589, 1995).
  • the invention achieves these objects and other objects and advantages which will become apparent from the description which follows by providing two novel mammalian genes Mammalian Ena (Mena), and Ena-VASP like (Evl) encoding novel proteins Mena, and Evl.
  • the Mena and Evl proteins provided herein possess novel biochemical and cell biological properties rendering these proteins useful in the study and/or control of a variety of microfilament dynamic processes.
  • the Mena and Evl proteins disclosed herein are useful for generating, isolating, and characterizing additional endogenous and exogenous factors, drugs and other agents useful for evaluating and/or controlling cytoskeletal dynamics involved in normal and abnormal cell morphology, adhesion, motility, growth and/or differentiation. Reflective of these uses, the invention provides several methods and tools specifically directed to the diagnosis and treatment of injury and disease conditions involving cytoskeletal dynamic processes, such as metastatic cancer and infection by cytopathogenic bacteria.
  • purified and isolated polynucleotides which encode a native Mena or Evl protein.
  • these polynucleotides are DNA sequences encoding specific native isoforms of Mena, including an approximately 140 kD, neural-specific isoform of Mena, an approximately 60 kD hematopoietic-specific Mena isoform, and approximately 80 kD and 88 kD isoforms of Mena which are broadly distributed among different mammalian tissue types.
  • Mena or Evl based polynucleotides that encode Mena or Evl proteins or fragments thereof, recombinantly produced peptide derivatives, fusion proteins and the like incorporating only a portion of Mena or Evl, and up to the entire Mena or Evl protein.
  • Mena or Evl based polynucleotides are sequences that encode discrete functional domains of the Mena or Evl protein responsible for specific biological activities of the intact protein.
  • Preferred functional domains in this context include an N-terminal domain of Mena and Evl that mediates binding of Mena to certain proline-rich ligands, including ActA, zyxin and vinculin, and which directs localization of Mena and heterologous proteins linked to the EVHl domain to focal contacts, and to the surface of cytopathogenic bacteria. Also provided are mutagenized polynucleotides that encode mutant analogs of the Mena or Evl protein, or of selected polypeptide portions of Mena or Evl such as the EVHl functional domain, which exhibit modified biological activity compared to native Mena or Evl proteins and polypeptide domains.
  • substantially pure Mena or Evl proteins are provided, including a variety of tissue specific or broadly distributed Mena and Evl isoforms disclosed herein. Also provided are Mena or Evl based synthetic peptides or fragments thereof, recombinantly produced peptides, fusion proteins and the like incorporating all or a portion of Mena or Evl, including peptides corresponding to the aforementioned Mena or Evl functional domains, as well as mutant analogs of the Mena or Evl protein or polypeptide portions thereof.
  • antibodies, antibody derivatives and chimeric antibodies are provided that bind to one or more of the Mena and Evl proteins and isoforms thereof. Also provided are antibodies, antibody derivatives and chimeric antibodies that bind to one or more of the Mena or Evl based synthetic peptides, recombinantly produced peptides, fusion proteins and the like disclosed herein.
  • Mena or Evl based recombinant polynucleotide expression constructs which include a polynucleotide insert encoding a Mena or Evl protein or Mena or Ena based synthetic peptide, recombinantly derived peptide, fusion protein or the like operably incorporated within an expression vector capable of directing expression of the polynucleotide insert sequence in a mammalian host cell.
  • Various such constructs are provided, including constructs that incorporate polynucleotide sequences encoding the native 140 kD, 60 kD, 80 kD or 88 kD Mena isoforms.
  • Mena or Evl based expression constructs are employed in methods for modulating expression oTMena or Evl, disrupting Mena or Evl expression or inducing ectopic expression of Mena or Evl genes and related polynucleotide sequences in mammalian host cells.
  • the expression constructs are introduced into the host cells by microinjection, transfection or other suitable method to achieve transformation of the host cell, and the host cell is cultured, transplanted or left in situ under suitable conditions to allow the host cell to express the Mena or Evl based polynucleotide insert sequence
  • a variety of screening and diagnostic methods and compositions are provided that employ one or more of the aforementioned inventive tools
  • the invention provides screening, diagnostic and therapeutic methods that utilize Mena or Evl encoding polynucleotides, Mena or Evl proteins, peptides, fusion proteins and the like, Mena or Evl binding antibodies, Mena or Evl based expression constructs, and/or mammalian host cells transformed to express Mena or Evl insert sequences
  • labeled Mena or Evl proteins and peptides are used to determine the localization and activity of Mena or Evl in normal and abnormal cytoskeletal dynamic processes
  • labeled Mena proteins, peptides and antibodies are introduced into the cytoplasm of Listeria infected cells to detect and quantify recruitment of Mena to the bacterial surface at the polar site of comet tail formation, and to detect and quantify the activity of Mena in mediating Listeria induction of microfilament polymerization
  • labeled Mena and anti-Mena antibodies are used to detect and quantify Mena binding to ActA profilin, zyxin or vinculin
  • Mena or Evl proteins and peptides are used to detect and quantify Mena or Evl activity in normal and abnormal cytoskeletal dynamic processes under endogenous control
  • Mena or Evl activity in normal and abnormal cytoskeletal dynamic processes under endogenous control
  • labeled Mena protein is used as a reagent to screen small molecule and peptide libraries to identify inhibitors of Mena activity
  • an overlapping set of chemically synthesized peptides is generated covering the sequence of a selected Mena ligand, such as ActA, Profilin or Zyxin, and this library is screened using covalently or antibody labeled Mena to identify
  • Mena or Evl based synthetic peptides, recombinantly produced peptides, fusion proteins and the like incorporating all or a portion of Mena or Evl, as well as mutant analogs of Mena or Evl proteins or peptides are used to screen for specific agonists and antagonists of Mena or Evl activities.
  • the EVHl domain of Mena or Evl, or an EVHl consensus peptide having a conserved amino acid sequence between Mena, Evl and VASP is used as an affinity reagent to identify as yet unknown cellular factors involved in cytoskeletal regulation, or as a labeled probe to screen cDNA expression libraries to identify genes encoding such unknown regulatory factors.
  • Other screening and diagnostic methods of the invention rely on labeled polynucleotide probes to map the chromosomal locations of Mena, Evl and related genes, to identify genetic defects in these genes among cell populations or individuals, and to detect and measure expression of Mena, Evl or related genes in association with specific cytoskeletal dynamic structures, events or molecular regulatory factors.
  • the invention provides a range of therapeutic methods for preventing and/or treating diseases and other conditions that involve aberrant cytoskeletal regulation, for example pathogenic infection, traumatic neural injury and cancer.
  • Therapeutic methods of the invention variously utilize Mena or Evl encoding polynucleotides, Mena or Evl proteins and peptides, Mena or Evl binding antibodies, Mena or Evl based expression constructs, mammalian host cells transformed to express Mena or Evl insert sequences, and other therapeutic agents such as triplex forming oligonucleotides, antisense polynucleotides or ribozymes that specifically target Mena and/or Evl polynucleotides.
  • agents that inhibit Mena or Evl expression or activity and thereby eliminate or impair aberrant recruitment of Mena by pathogens, or interrupt Mena expression or activity associated with cancerous cell migration.
  • Useful inhibitors in this context include antibodies that block or impair Mena or Evl by binding to the protein, Mena or Evl based, synthetic or recombinantly produced peptides, fusion proteins that compete for Mena or Evl binding partners or otherwise block or impair Mena or Evl expression or activity, triplex forming oligonucleotides, antisense polynucleotides or ribozymes that block expression of Mena and/or Evl polynucleotides, and mutant Mena or Evl based expression constructs that abolish or reduce Mena or Evl expression or activity in targeted cells.
  • agents that induce or enhance Mena or Evl expression or activity include anti-Evl antibodies, Mena or Evl based, synthetic or recombinantly produced peptides, fusion proteins and the like that enhance Mena or Evl binding to its partners or otherwise enhance Mena or Evl expression or activity, and mutant Mena or Evl based expression constructs that induce or enhance Mena or Evl expression or activity in targeted cells.
  • the present invention provides two novel mammalian genes Mammalian Ena (Mena), and Ena-VASP like (Evl) which encode novel proteins Mena, and Evl.
  • Mena Mammalian Ena
  • Evl Ena-VASP like
  • Sequences encoding Mena and Evl include those sequences that result in minor variations in amino acid sequence, such as those due to genetic polymorphisms, allelic variations, differences between species and those in which blocks of amino acids have been added, altered or replaced without substantially altering the biological activity of the proteins.
  • Mena and Evl genes and Mena and Evl proteins disclosed herein are useful for generating, isolating, and characterizing endogenous and exogenous factors, drugs and other agents that can be employed in methods to evaluate and/or regulate cytoskeletal dynamic processes involved in normal and abnormal cell morphology, adhesion, motility, growth and/or differentiation.
  • the invention provides specific methods directed toward the diagnosis and treatment of injury and disease conditions involving cytoskeletal dynamic processes, such as metastatic cancer and infection by cytopathogenic bacteria.
  • purified and isolated polynucleotides which encode a native Mena or Evl protein.
  • these polynucleotides are DNA sequences encoding specific isoforms of native Mena or Evl.
  • Preferred methods to isolate and purify polynucleotides encoding native Mena or Evl employ conventional screening, subcloning and polymerase chain reactions, for example according to the methods and using the reagents described in Sambrook et al., (1989) Molecular Cloning A Laboratory Manual (Cold Spring Harbor, NY: Cold Spring Harbor Press).
  • a restriction fragment of the Drosophila gene Ena (Gertler et al., Genes Dev.
  • Additional polynucleotide probes that are useful within the invention include Mena or Evl probes corresponding to partial or complete nucleotide sequences generated from the cDNAs depicted in SEQ ID. NOS: 1, 3 or 7 below. Degenerate oligonucleotides based on the amino acid sequences of SEQ ID NOS: 2, 4, 5, 6, 8 and 9 are also useful in methods for identifying additional isoforms and related sequences.
  • proteins, synthetic peptides, recombinantly produced peptides, fusion proteins and the like that bind or otherwise interact with Mena can be used as labeled probes to screen mammalian cDNA expression libraries to identify additional genes or cDNAs encoding Mena or Evl proteins.
  • known Mena binding partners including ActA zyxin, vinculin and VASP, are used as probes to detect Mena encoding polynucleotides, for example using well known autoradiographic or immunoassay screening methods.
  • hybridization conditions will be evident to one skilled in the art and will generally be guided by the purpose of the hybridization, the type of hybridization (DNA- DNA or DNA-RNA), and the level of relatedness between the sequences.
  • Methods for hybridization are well established in the literature; See, for example: Sambrook, ibid., Hames and Higgins, eds, Nucleic Acid Hybridization A Practical Approach, IRL Press, Washington DC, 1985; Berger and Kimmel, eds, Methods in Enzymology, Vol. 52. Guide to Molecular Cloning Techniques. Academic Press Inc., New York, NY, 1987; and Bothwell, Yancopoulos and Alt, eds, Methods for Cloning and Analysis of Eukaryotic Genes.
  • Hybridization stringency can be altered by: adjusting the temperature of hybridization, adjusting the percentage of helix-destabilizing agents, such as formamide, in the hybridization mix; and adjusting the temperature and salt concentration of the wash solutions. In general, the stringency of hybridization is adjusted during the post- hybridization washes by varying the salt concentration and/or the temperature.
  • Stringency of hybridization may be reduced by reducing the percentage of formamide in the hybridization solution or by decreasing the temperature of the wash solution.
  • High stringency conditions may involve high temperature hybridization (e.g., 65-68°C in aqueous solution containing 4- 6XSSC, or 42°C in 50% formamide) combined with high temperature (e.g., 5-25°C below the T m ) and a low salt concentration (e.g., 0.1X SSC).
  • Reduced stringency conditions may involve lower hybridization temperatures (e.g., 35-42°C in 20-50% formamide) with intermediate temperature (e.g., 40-60°C) and washes in a higher salt concentration (e.g., 2- 6X SSC).
  • Moderate stringency conditions which may involve hybridization at a temperature between 50°C and 55°C and washes in 0. Ix SSC, 0.1% SDS at between 50°C and 55°C, may be used to identify clones encoding polynucleotide molecules encoding Mena or Evl from other species or to isolate isoforms of Mena or Evl.
  • Mena or Ena encoding polynucleotides that are particularly useful within the invention encode Mena or Ena proteins having unique structural and/or biochemical properties, or which exhibit discrete expression or tissue distribution patterns among a various Mena or Ena isoforms.
  • SEQ ID NO: 1 depicts a Mena cDNA polynucleotide and is deduced amino acid sequence (SEQ ID NOS: 1 and 2) evidently expressed in two isoforms, approximately 80 kD, and 88 kD in size, and exhibiting a broad pattern of tissue distribution in neurons, fibroblasts, kidney epithelium, muscle, neural crest and hematopoietic cells.
  • Neural Mena cDNA polynucleotides that contain combinations of three alternately included exons and encoding multiple isoforms of Mena (Neural Mena + , SEQ ID NO: 4; Neural Mena ++ , SEQ ID NO: 5; and Neural Mena +++ , SEQ ID NO: 6).
  • a cDNA encoding Neural Mena 4 is disclosed (SEQ ID NO: 3) Unlike Mena, Neural Mena isoforms are approximately 140 kD in size and exhibit neural tissue specific distribution.
  • cDNA polynucleotides encoding an approximately 60 kD, hematopoietic specific form of Mena, and cDNA polynucleotides (SEQ ID NOS: 7) encoding the Evl protein (SEQ ID NO: 8) are described.
  • molecular size of proteins translated from Mena or Ena coding cDNAs in vitro can be determined by gel electrophoresis, and tissue distribution can be determined by comparative Western blotting of cell iysates from different tissues, or in situ hybridization of whole embryos or tissue sections, using anti-Mena or anti-Evl antibodies (for example according to the general methods disclosed in Harlow and Lane, (1988) Antibodies A Laboratory Manual (Cold Spring Harbor, NY: Cold Spring Harbor Press), which is incorporated herein by reference in its entirety).
  • tissue specificity of Mena or Ena encoding polynucleotides include assays that measure Mena or Ena expression between tissue differentiation stages, for example in in vivo developmental models or systems where tissue differentiation can be induced by exogenous stimuli.
  • Mena protein is assayed by direct anti-Mena immunofluorescence assay in developing embryos and in differentiated P19 embryonic carcinomal cells, to demonstrate that expression of the 140 kD neural specific Mena isoform increases during development at the time of rapid neurite outgrowth, and that subcellular distribution of Neural Mena in P19 cells is concentrated in the growth cones of developing neurites.
  • Mena or Evl based polynucleotides that encode Mena or Evl proteins or fragments thereof, recombinantly produced peptide derivatives, fusion proteins and the like incorporating only a portion of Mena or Evl, and up to the entire Mena or Evl protein.
  • Mena or Evl based polynucleotides are sequences that encode discrete functional domains of the Mena or Evl protein responsible for specific biological activities of the intact protein.
  • N-Mena N-terminal domain of Mena (N-Mena) including approximately the first 170 amino acids of the protein is demonstrated to mediate binding of Mena to certain proline-rich ligands, including ActA, zyxin and vinculin, and to direct localization of Mena and heterologous proteins linked to the N-Mena peptide to focal contacts, and to the surface of cytopathogenic bacteria.
  • the N-Mena peptide corresponds to a functional domain (the EVHl domain) that is highly conserved between Mena, Evl and VASP, as demonstrated by sequence alignment comparisons. A consensus sequence for the alignment is shown in SEQ ID NO. 9.
  • substantially pure Mena or Evl proteins and peptides are provided that are initially encoded by the aforementioned polynucleotides.
  • the Mena and Evl proteins include a variety of tissue specific or broadly distributed Mena and Evl isoforms disclosed herein.
  • Mena or Evl based synthetic peptides, recombinantly produced peptides, fusion proteins and the like incorporating all or a portion of Mena or Evl, including peptides corresponding to the aforementioned Mena or Evl functional domains, as well as mutant analogs of the Mena or Evl protein or polypeptide portions thereof.
  • the proteins or polypeptide portions thereof may or may not have the biological activity of corresponding native Mena or Evl.
  • proteins are prepared that are capable of binding to the proline-rich binding partner ActA but not capable of inducing profilin.
  • the peptides can be prepared via chemical synthesis, as described hereinbelow, or by recombinant DNA technology, or as fusion proteins, and the like. Desirably, the peptide will be as small as possible while still maintaining substantially all of the reactivity of a larger peptide.
  • the subject peptides have an amino acid sequence encoded by a nucleic acid which hybridizes under stringent conditions with an oligonucleotide of 15 or more contiguous nucleotides of SEQ ID NOS: 1,3, or 7. Exemplary amino acid sequences among the subject peptides are shown in SEQ ID NO: 2 (amino acids 6-170 (N-Mena); amino acids 440-537 (C-Mena) and SEQ ID NO: 11.
  • the peptides of the present invention or analogs thereof which have Mena or Evl activity may be modified from a native Mena or Evl sequence as necessary to provide other desired attributes, e.g., improved binding or inhibitory activity (e.g., increased competition with native protein), improved adsorption to a solid phase, etc.
  • the peptides may be subject to various changes, such as insertions, deletions, and substitutions, either conservative or non- conservative, where such changes might provide for certain advantages in their use.
  • conservative substitutions is meant replacing an amino acid residue with another which is biologically and/or chemically similar, e.g., one hydrophobic residue for another, or one polar residue for another.
  • substitutions include combinations such as Gly, Ala; Val, He, Leu; Asp, Glu; Asn, Gin; Ser, Thr; Lys, Arg; and Phe, Tyr.
  • sequence of the peptide will not differ by more than about 20% from the native Mena or Evl sequence, except where additional amino acids may be added at either terminus for the purpose of modifying the physical or chemical properties of the peptide for, e g , ease of linking or coupling, and the like. Having identified different peptides of the invention, in some instances it may be desirable to join two or more peptides in a composition or admixture.
  • the peptides in the composition can be identical or different, and together they should provide equivalent or greater reactivity than the parent peptide(s).
  • the subject peptides find a variety of uses including preparation of specific antibodies. Because of their relatively short size, the peptides can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. See, for example, Stewart and Young, Solid Phase Peptide Synthesis. 2d. ed., Pierce Chemical Co. (1984); Tarn et al., J. Am. Chem. Soc.
  • Short peptide sequences, or libraries of overlapping peptides usually from about 6 up to about 35 to 50 amino acids, which correspond to the selected regions described herein, can be readily synthesized and then screened in screening assays designed to identify reactive peptides.
  • recombinant DNA technology may be employed wherein a nucleotide sequence which encodes a peptide of the invention is inserted into an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression.
  • Evl can be detected and quantified using a variety of methods, including for example ligand binding assays using immobilized Mena or Evl proteins or fusion proteins.
  • PCR is used to generate polynucleotide fragments encoding amino acids corresponding to a selected or putative functional domain, for example amino acids 6-170 representing N-Mena, or amino acids 440-537 representing a C-terminal functional domain of Mena (C-Mena).
  • the polynucleotide fragments are then cloned into a suitable expression vector, for example pGex2T, and fusion proteins are prepared (Smith and Johnson, Gene 67: 31-40, 1988, which is incorporated herein by reference in its entirety).
  • the fusion proteins can be endogenously labeled, for example using a covalent radiolabel or other conventional marker, or alternately labeled using antibodies that bind to the fusion protein.
  • an N-Mena-Gst fusion protein was generated and immobilized on glutathione-agarose bead matrix (SEPHAROSE; Pharmacia Biotech, Inc., Piscataway, NJ). Proteins capable of binding N-Mena-Gst were then purified from head Iysates of stage E12 mouse embryos, or human erythrocytic leukemia cells (HEL). Bound proteins were analyzed by Western blotting with antibodies to ActA zyxin, vinculin or the Ack kinase.
  • N-Mena binds to Act zyxin and vinculin, but not to Ack. More specific examples, employing ligand overlay assays using peptides derived from vinculin or ActA (for example according to the methods of Chakraborty et al. EMBO J. 14: 1314-1321, 1995) demonstrate that N-Mena can associate with motifs common to ActA zyxin and vinculin.
  • the activity of N-Mena and other functional domains of Mena and/or Evl in cytoskeletal dynamic processes can be further evaluated and incorporated within the methods of the invention using a variety of additional tools that are disclosed herein, or are elsewhere described and known in the art.
  • purified Gst-N- Mena is microinjected into PtK 2 cells seeded to semi-confluency on CELLocate coverslips (Eppendorf, Hamburg, Germany), and anti-Gst antibody assays coupled with phalloidin labeling to show the distribution of microfilaments is used to demonstrate that the injected fusion protein localizes to focal adhesions, whereas Gst injected atone is diffusely localized throughout the cytoplasm. Subsequently a peptide containing the ActA sequence SEPSSFEFPPPPTDEELRLA (SEQ ID NO: 12) is injected into the cells in an attempt to saturate the N-Mena binding site for ActA.
  • SEPSSFEFPPPPTDEELRLA SEQ ID NO: 12
  • the activity of Mena or Evl and N-Mena and other functional domains of Mena and/or Evl in cytoskeletal dynamic processes can be further evaluated and incorporated within the methods of the invention with the aid of protein crystallography.
  • the basic protein expression methods of the invention provide for the production of sufficiently large amounts of pure Mena and Evl protein to allow crystallographic analysis of Mena and Evl bound and unbound to their various binding partners. These studies will further elucidate the complex structure and function of the Mena and Evl proteins and will be of substantial value in the design of small molecule inhibitors of these proteins.
  • N-Mena and other functional domains of Mena and/or Evl in cytoskeletal dynamic processes can be further evaluated and incorporated within the methods of the invention in the context of pathogenic induction of cytoskeletal dynamic processes.
  • purified Gst-N-Mena was microinjected into PtK 2 cells which were then infected with Listeria.
  • Anti-Gst immunoassay coupled with phalloidin labeling shows that the Mena based fusion protein associates with the surface of the bacteria and overlaps with actin in the region of actin polymerization at the tail of the bacterium, similar to the distribution of endogenous Mena in Listeria infected cells.
  • Mena protein translated in vitro binds immobilized profilin, which binding is reduced by six-fold following pre-incubation of the profilin matrix with a (GPj) 3 peptide (SEQ ID NO: 12) corresponding to the profilin-binding motif of VASP (Reinhard et al., EMBO J. 14: 1583-1589, 1995, which is incorporated herein by reference in its entirety).
  • GPj GPj 3 peptide
  • VASP profilin-binding motif of VASP
  • the general methods and compositions described above for localizing and quantifying Mena or Evl associated with dynamic cytoskeletal structures or events, and for determining Mena activity in association with specific factors and events involved in cytoskeletal regulation provides the basis for a variety of methods to diagnose and treat abnormal cytoskeletal processes associated with pathogenic infection, disease and other conditions, and to screen for agonists and antagonists of specific Mena activities involved in such processes.
  • a particularly useful set of tools in this context includes the various antibodies provided within the invention for detecting Mena and/or Evl expression, activity and localization.
  • Antibody reagents useful for these purposes include antibodies, antibody derivatives and chimeric antibodies that bind to one or more of the Mena and Evl proteins and isoforms thereof. Also provided are antibodies, antibody derivatives and chimeric antibodies that bind to one or more of the Mena or Evl based synthetic peptides, recombinantly produced peptides, fusion proteins and the like disclosed herein.
  • non-human antisera or monoclonal antibodies e.g., murine, lagormorpha, porcine, equine
  • immunizing an animal with Mena protein or Mena based peptides or alternatively with Evl protein or Evl based peptides e.g., murine, lagormorpha, porcine, equine
  • Evl protein or Evl based peptides e.g., murine, lagormorpha, porcine, equine
  • monoclonal antibodies to Mena antibody producing cells are obtained from immunized animals, immortalized and screened, or screened first for the production of an antibody that binds to the Mena protein or peptides and then immortalized.
  • a human monoclonal antibody or portions thereof may be identified by first screening a human B-cell cDNA library for DNA molecules that encode antibodies that specifically bind to Mena according to the method generally set forth by Huse et al. (Science 246: 1275-1281, 1989, which is incorporated by reference herein in its entirety). The DNA molecule may then be cloned and amplified to obtain sequences that encode the antibody (or binding domain) of the desired specificity.
  • Anti-Mena or anti-Evl antibodies are particularly useful within the invention as labeled reagents to detect, image and/or quantify the presence or activity of Mena or Evl, or of agonists or antagonists of Mena or Evl activity.
  • anti-Mena and anti- Evl antibodies are provided which incorporate one or more well known labels such as a dye, fluorescent tag or radiolabel.
  • Anti-Mena or anti-Evl antibodies may also be used themselves as agonists or antagonists of Mena or Evl activity, for example by interfering with the binding of Mena to ActA, profilin, zyxin or vinculin.
  • anti-Mena or anti-Evl antibodies may be used as targeting agents for the delivery of compounds of therapeutic interest.
  • compounds include, but are not limited to, toxins, cytostatic compounds, or proenzymes whose potential function is to activate endogenous proenzymes, to activate proenzymes from exogenous sources, or to activate enzyme cleavage sites on prodrugs.
  • bifunctional antibodies having independent antigen binding sites on each immunoglobulin molecule (as disclosed for example in Thromb. Res. Suppl. X: 83, 1990, and in The Second Annual IBC International Conference on Antibody Engineering. A. George ed., Dec. 16-18, 1991), as well as panels of antibodies having differing specificities.
  • Bifunctional antibodies and antibody panels of particular use within the invention include antibodies and panels of antibodies that bind to both Mena and Evl, or to multiple functional domains of the Mena or Evl protein.
  • the subject proteins and peptides of the invention are also useful as reagents to detect, image and/or quantify the presence or activity of Mena or Evl, or of agonists or antagonists of Mena or Evl activity, in addition to their usefulness in the preparation of anti- Mena and anti-Evl antibodies.
  • a collection of Mena or Evl proteins substantially purified are provided, including all of the Mena and Evl isoforms disclosed herein.
  • the Mena and Evl proteins produced according to the present invention may be purified using a number of established methods such as affinity chromatography using anti- Mena or anti-Evl antibodies coupled to a solid support.
  • Additional purification may be achieved using conventional purification means such as liquid chromatography, gradient centrifugation and gel electrophoresis among others.
  • Methods of protein purification are known in the art (see generally, Scopes, R., Protein Purification. Springer- Verlag, NY, 1982, which is incorporated herein by reference) and may be applied to the purification of recombinant Mena or Evl described herein.
  • Mena and Evl are provided isolated from its natural cellular environment, and substantially free of other cellular proteins.
  • Purified Mena and Evl are provided, where substantially pure Mena and Evl of at least about 50% is preferred, at least about 70-80% is more preferred, and 95-99% or more homogeneity most preferred.
  • the recombinant Mena and Evl or native Mena and Evl may be used to generate antibodies, diagnostically in assay procedures, etc.
  • Proteins, peptides and fusion proteins of the invention may be selected to include one or more of the Mena or Evl functional domains disclosed herein, as well as mutant analogs of the Mena or Evl protein or polypeptide which exhibit modified biological activity compared to native Mena or Evl proteins and polypeptide domains.
  • the proteins, peptides and fusion proteins of the invention are provided according to the methods disclosed herein, as well as by additional recombinant, biosynthetic and peptide chemical methods described elsewhere and generally known in the art.
  • site directed mutagenic techniques that can be used to generated targeted mutations in specific regions or functional domains of a Mena or Evl based polynucleotide.
  • site directed mutagenesis within the EVHl domain encoding portion oTMena will yield Mena mutants that are either hyperfunctional or dominant negative with respect to Mena activities attributable to the EVHl domain, including ActA zyxin and vinculin binding activities, and subcellular localization of Mena.
  • Such mutants can be useful by themselves in various applications, or combined with other native or mutant peptide sequences, labels or other agents for more specific purposes.
  • an N-Mena mutant having an enhanced Act zyxin or vinculin binding activity selective for a specific binding partner can be used to screen for particularly strong or specific antagonists that inhibit that specific binding activity.
  • hyperfunctional N-Mena mutants will be particularly useful as gene therapeutic agent to induce or enhance Mena function in impaired systems, such as in the case of a neural injury or wound healing condition.
  • hyperfunctional N-Mena mutants can be operably joined to other peptide sequences, labels or chemical agents to achieve a particular therapeutic value.
  • One such chimeric mutant is contemplated having a hyperfunctional N-Mena mutation as well as a dominant negative mutation in the proline rich, profilin binding domain.
  • This particular chimera will compete strongly with endogenous Mena for ActA, zyxin and vinculin binding, but will fail to promote wild type profilin binding and microfilament assembly.
  • Such a mutant will be useful tool in a variety of applications, for example to screen for agonists that replace or enhance Mena-profilin binding activity, or as a gene therapeutic agent capable of inhibiting endogenous Mena function in aberrant migratory cells, such as Chronic Myelogenous Leukemia (CML) and other cancer cells.
  • CML Chronic Myelogenous Leukemia
  • Mena or Evl proteins, peptides, fusion proteins and antibodies are used in a variety of screening and diagnostic methods.
  • the polynucleotide molecules, protein, peptides and antibodies of the present invention or useful in in vitro assays to screen for compounds capable of modulating the activity of expression of Mena or Evl.
  • test compounds may be assessed for their ability to increase or decrease Mena activity or expression relative to a control assay in which the test compound is absent. Screening assays of the present invention exploit the binding of Mena and Evl to different substrates.
  • test compounds are screened for the ability to compete with Mena binding partners such as ActA profilin, Zyxin or Vinculin.
  • test compounds are screened for the ability to modulate Mena or Evl activity by increasing or decreasing Mena or Evl expression.
  • labeled Mena or Evl proteins, peptides, or anti- Mena or anti-Evl antibodies are employed to detect expression, localization and/or activity of Mena or Evl associated with normal and/or abnormal cytoskeletal structures or processes, or in association with specific molecular factors involved in cytoskeletal regulation.
  • Mena or Evl expression or activity is detected and/or quantified in a normal cell population or tissue, and these results are compared to Mena or Evl expression or activity detected and/or quantified in a test cell population or tissue (for example a population of cancerous cells or cells from a site of neural injury).
  • Detection and/or quantification of Mena or Evl expression, localization or activity can be accomplished by a variety of methods, such as by in situ hybridization using anti-Mena or anti-Evl antibodies on embryos or tissue sections or within antibody microinjected cells, by Western blotting or immunoprecipitation using anti-Mena or anti-Evl antibodies in cell or tissue iysates, or by affinity purification using anti-Mena or anti-Evl antibodies bound to a solid phase, among other methods. Comparable methods are disclosed herein, or are elsewhere disclosed and known in the art, for using non-antibody agents to detect and/or quantify Mena or Evl expression or activity.
  • Suitable non-antibody probes for use within these methods include for example oligonucleotide probes that hybridize to Mena or Evl transcripts, labeled binding partners of Mena or Evl such as ActA, zyxin, vinculin or profilin, and synthetic or recombinant peptide analogs of Mena or Evl binding partners, among other useful probe types.
  • Mena and Evl cDNA and oligonucleotide probes may be useful in Northern, Southern, and dot-blot assays for identifying and quantifying the level of expression of Mena or Evl in a cell.
  • Measuring the level of Mena or Evl expression may provide prognostic markers for assessing the growth rate and invasiveness of tumors.
  • birth defects and abortions may result from the absence or expression of an abnormal Mena protein.
  • Mena may be useful in prenatal screening of mothers and/or for in utero testing of fetuses.
  • Differences that are detected and/or quantified between Mena or Evl expression or activity between normal and test cell populations or tissues may be diagnostic of particular disease states or other conditions characterized by aberrant cytoskeletal structure or regulation.
  • an increase of Mena expression compared to control cells is predictive of an increased risk of metastatic disease due to Mena-mediated cell motility and reduction of contact inhibition.
  • the level of Mena expression or activity compared to control cells is predictive of the extent of neural regeneration that can be expected in a particular case, and may also be useful for determining preferred courses of treatment.
  • the presence and pattern of Mena expression in association with the pathogen provides a positive diagnosis of the type of infection, and the level of Mena expression or activity compared to control cells is diagnostic of the severity of infection.
  • Additional diagnostic methods of the invention rely on labeled polynucleotide probes to map the chromosomal locations of Mena, Evl and related genes, to determine linkage of these genes relative to other genes, and to identify genetic defects in these genes among cell populations or individuals.
  • Mena was demonstrated by genetic linkage analysis to be located in the mouse to chromosome la offset 73 in the Jackson backcross hybrid mapping panel. This location in the mouse is syntenic to a human chromosomal position of 1Q21-23 (Stanier et al., Genomics 26: 473- 478, 1995), which location adds significance to the methods of the invention because it is a putative hot spot for breast cancer.
  • Cytoskeletal dynamic processes are mediated by a variety of signal cascades that can be induced by external stimuli such as adhesion through integrins or stimulation with a growth factor such as PDGF. Many of these signals are propagated in part by kinase cascades that may trigger Mena phosphorylation.
  • Src family kinases are concentrated in neuronal growth cones (Bixby and Jhabvala, J. Neurosci.
  • c-Src may be required for proper neurite outgrowth on the cell adhesion molecule LI (Ignelzi et al., Neuron 12:, 873-84, 1994).
  • Mammalian c-Abl is a another logical candidate Mena kinase. From studies in N1H3T3 cells, c-Abl is widely perceived as a largely nuclear tyrosine kinase. However, in P19 neurons, Abl is found exclusively in the cytoplasm and in growth cones. A role for cytoplasmic c-Abl in actin dynamics is indicated by the presence of G- and F-actin binding activities in its C-terminus (McWhirter et al., Mol. Cell. Bjol. 13, 7587-95, 1993; McWhirter et al., Mol. Cell. Biol. JJ . , 1553-1565, 1991 ;
  • Mena contains serine residues aligning to known cyclic nucleotide kinase-dependent phosphorylation sites in VASP (Butt et al., J. Biol. Chem. 269: 14509-17, 1994). These serine residues in Mena flank the central proline-rich region of the protein.
  • Evl contains the amino-terminal site only, while Ena lacks both sites.
  • a slower migrating form of Mena is less efficiently recovered in SH3 binding assays than a faster form.
  • the alternatively-included portions of the 140 kD Mena isoform may contain the phosphorylated tyrosine(s), or sequences that recruit Mena kinases.
  • Screening methods that are particularly useful within the invention include high throughput screening assays designed to identify modulators of Mena or Evl expression or activity.
  • labeled Mena or Evl proteins, peptides, or anti-Mena or anti-Evl antibodies are employed in a similar manner as described above to detect and/or quantify expression or activity of Mena or Evl in comparable test and control samples.
  • Useful control samples in this context generally include a variety oTin vivo or in vitro assay mixtures suitable for detecting and/or quantifying Mena or Evl binding to a selected binding partner, for example ActA, zyxin, vinculin or profilin.
  • Other suitable control samples include in vivo or in vivo assays mixtures suitable for detecting other activities of Mena or Evl, for example subcellular localization of Mena to the surface of a cytopathogenic bacteria or a site of endogenously controlled microfilament formation, or Mena or Evl phosphorylation.
  • Useful test samples within these screening methods contain an added test substance, i.e.
  • the test sample contains suitable amounts of Mena or Evl protein and a selected binding partner under conditions that permit the formation of Mena- or Evl-binding partner complexes in the absence of the test substance.
  • the complexes are then detected and/or quantified according the methods disclosed herein, and these results are compared to the results of detection and/or quantification of Mena- or Evl-binding partner complexes formed in the control sample.
  • kits and multicontainer units comprising reagents and components for practicing the assay methods of the present invention.
  • Kits of the present invention may, in addition to reagents for detecting Mena and Evl, contain enzymatic reagents such as reverse transcriptase or polymerase; suitable buffers; nucleoside triphosphates; suitable labels for labeling the reagents for detecting Mena and Evl and developing reagents for detecting the signal from the label.
  • kits of the present invention contain sequence- specific oligonucleotide primers for detecting polynucleotide molecules encoding Mena and Evl.
  • kits containing Mena and Evl sequence-specific probes contain antibodies useful for detecting Mena and Evl (or mutants thereof) in a sample.
  • kits contain Mena- and/or Evl-specific antibodies for detecting Mena and Evl protein.
  • the Mena and Evl-specific antibodies may be labeled or may be detected by binding to a secondary antibody.
  • the antibody reagents may be provided in separate container or may be provided in combination in a series of containers.
  • the kits may also contain instructions for carrying out the assay and/or additional containers suitable for carrying out the reactions of the assay.
  • the complex structure of the Mena and Evl proteins, and the various biological activities of EVHl and other functional domains of Mena or Evl, provide for a broad array of potential screening assays and assay formats.
  • ligand binding assays using immobilized Mena or Evl proteins or fusion proteins are preferred for high throughput screening purposes.
  • labeled Mena or Evl proteins or Mena or Evl based peptides or fusion proteins are immobilized on a solid phase, for example, an N-Mena-Gst fusion protein immobilized on a glutathione-agarose bead matrix such as glutathione SEPHAROSE (Pharmacia Biotech, Inc., Piscataway, NJ).
  • the control assay sample is completed by exposing the bound N-Mena-Gst fusion protein to a N- Mena ligand, for example ActA, zyxin or vinculin.
  • the ligand may be provided in a purified form, or as a component of a ligand-containing mixture, for example a cell or tissue lysate.
  • N-Mena-ligand complexes are detected and/or quantified following exposure of the ligand to the bound fusion protein using any of a variety of detection or quantification methods disclosed herein, for example by a selected immunoassay using antibodies to ActA, zyxin or vinculin.
  • the test assay sample is prepared in a comparable fashion, by exposing the bound N-Mena-Gst fusion protein to an N-Mena ligand under conditions that permit formation of N-Mena-ligand complexes in the control assay sample.
  • test substances useful within the invention may include substances present throughout the handling of test sample components, for example host cell factors that are present in a cell lysate used for generating the test sample. Such endogenous factors may be segregated between the test and control samples for example by using different cell types for preparing Iysates, where the cell type used for preparing the test sample expresses a putative test substance that is not expressed by the cell type used in preparing the control sample.
  • a particularly useful set of test and control cell types in this context are P 19 embryonic carcinomal cells that have and have not been induced to undergo neural differentiation by retinoic acid.
  • test and control samples include reagents that are microinjected into cells to yield an in vivo assay mixture.
  • Gst-N-Mena is microinjected into PtK 2 cells seeded to semi-confluency on CELLocate coverslips (Eppendorf, Hamburg, Germany).
  • Labeled anti- Gst or anti-N-Mena antibodies are also injected or otherwise delivered (e.g. by microporation or liposomal transfection) into the cells.
  • a control sample of cells thus treated the pattern and/or intensity of antibody labeling is detected.
  • a test substance such as the ActA sequence SEPSSFEFPPPPTDEELRLA (SEQ ID NO: 12), is delivered into the cell prior to detecting the pattern and/or intensity of antibody labeling.
  • results of this form of assay can be readily determined based on simple qualitative observations, for example by immunofiuorescence visualization of Gst-N-Mena depletion from focal contacts, or from the surface of Listeria or other pathogens in infected cells, confined to the test sample.
  • EHEC EHEC
  • EHEC EHEC
  • EHEC EHEC
  • host cell tyrosine kinases and actin accumulation leading to profound host cytoskeletal disruption EHEC
  • diverse viral pathogens have recently been discovered to also cause profound changes in cytoskeletal dynamic processes.
  • the HIV virus spreads between cells via syncitia formation which involves both cell motility and reorganization of the cytoskeleton accompanied by condensation of F- Actin (Sylwester et al., J. Cell. Sci. 106: 941-53, 1993, which is herein incorporated by reference in its entirety).
  • vaccinia virus in its intracellular enveloped form induces the formation of actin tails that are "strikingly similar" to those seen in Listeria, Shigella and Rickettsia infections (Cudmore et al., Nature 378: 636-8, 1995, which is herein incorporated by reference in its entirety).
  • the screening methods of the invention will be particularly useful to identify negative modulators of Mena or Evl expression and/or activity. Once identified, these Mena or Evl inhibitors will supplement existing tools and methods within the invention for preventing and treating such pathogenic diseases.
  • Mena or Evl based recombinant polynucleotide expression constructs which include a polynucleotide insert encoding a Mena or Evl protein or peptides, fusion protein or the like operably incorporated within an expression vector capable of directing expression of the polynucleotide insert in a mammalian host cell.
  • Such constructs may include native or mutagenized forms of the Mena or Evl protein or of selected polypeptide portions of Mena or Evl such as the EVHl functional domain.
  • Various such constructs are provided, including constructs that incorporate polynucleotide sequences encoding the native 140 kD, 60 kD, 80 kD or 88 kD Mena isoforms, Evl or consensus sequences derived from SEQ ID NO: 9.
  • Cells transformed with these constructs may contain for example altered Mena coding sequences that result in the expression of a Mena protein that is not capable of binding to one or more of the EVHl domain ligands of Mena, including ActA zyxin and vinculin, or which has enhanced binding to profilin that results in a phenotype characterized by hyperfunctional actin polymerization.
  • the subject cell lines and animals find uses in screening for candidate therapeutic agents capable of either substituting for a function performed by Mena or correcting the cellular defect caused by a defective Mena.
  • polynucleotide molecules of the present invention may be joined to reporter genes, such as ⁇ -galactosidase or luciferase, and inserted into the genome of a suitable embryonic host cell such as an mouse embryonic stem cell by, for example, homologous recombination (for review, see Capecchi, Trends in Genetics 5: 70-76, 1989; which is incorporated by reference). Cells and cell lines expressing the subject molecules may then be obtained and used, for example, for screening for compounds that increase or decrease expression of the reporter gene.
  • reporter genes such as ⁇ -galactosidase or luciferase
  • mice are generated by replacing the murine Mena or Evl coding region with the ⁇ -galactosidase reporter gene and the neomycin resistance gene to assess the consequences of eliminating the murine Mena or Evl protein, and to examine the tissue distribution of Mena or Evl in fetal and post-natal mice.
  • These "Knock out" mice are useful for example as model systems for screening compounds that may developmentally, spatially and/or quantitatively alter the expression of the reporter gene. Such mice may be used to study methods to rescue homozygous mutants and as hosts to test transplant tissue for treating diseases or other conditions characterized by aberrant regulation of cytoskeletal dynamic processes.
  • the invention provides a range of therapeutic methods for preventing and/or treating diseases and other conditions that involve aberrant cytoskeletal regulation, for example pathogenic infection, traumatic neural injury and cancer.
  • Therapeutic methods of the invention variously utilize Mena or Evl encoding polynucleotides, Mena or Evl proteins and peptides, Mena or Evl binding antibodies, Mena or Evl based expression constructs, mammalian host cells transformed to express Mena or Evl insert sequences, and other therapeutic agents generally characterized as modulators of Mena or Evl expression or activity, including triplex forming oligonucleotides, antisense polynucleotides and ribozymes that specifically target Mena and/or Evl polynucleotides.
  • agents that inhibit Mena or Evl expression or activity In preferred therapeutic methods directed to the treatment of pathogenic infection and cancer, it is useful to employ agents that inhibit Mena or Evl expression or activity and which thereby can eliminate or impair aberrant recruitment of Mena by pathogens, or interrupt Mena expression or activity associated with cancerous cell migration.
  • agents that induce or enhance Mena or Evl expression or activity In preferred therapeutic methods directed to the treatment of traumatic neural injury and other injury conditions where it is desirable to promote cell migration for neural regeneration or wound healing, it is useful to employ agents that induce or enhance Mena or Evl expression or activity.
  • Useful agents in this context generally include agents that enhance Mena or Evl binding to its partners or otherwise enhance Mena or Evl expression or activity, for example mutant Mena or Evl based expression constructs that induce or enhance Mena or Evl expression or activity in targeted cells.
  • Therapeutic substances which can serve as inhibitors or antagonists of Mena or Evl include, but are not limited to, compounds capable of inhibiting the formation of Mena- profilin or Mena-proline-rich binding partner, compounds that reduce or inhibit the activity of Mena, and compounds that interfere with the expression of Mena protein.
  • Such agents may include chemical compound inhibitors of Mena, protein or peptide Mena antagonists, and molecules that inhibit the expression of Mena such as triplex forming oligonucleotides, antisense polynucleotides, ribozymes, etc.
  • antisense polynucleotides are described generally in, for example, Mol and Van der Krul, eds. r Antisense Nucleic Acids and Proteins Fundamentals and Applications. New York, NY, 1992, which is incorporated by reference herein in its entirety.
  • Suitable antisense oligonucleotides are at least 1 1 nucleotides in length and up to and including the upstream untranslated and associated coding sequences of Mena.
  • the optimal length of antisense oligonucleotides is dependent on the strength of the interaction between the antisense oligonucleotides and their complementary sequence on the mRNA, the temperature and ionic environment in which translation takes place, the base sequence of the antisense oligonucleotide, the presence of secondary and tertiary structure in the mRNA and/or in the antisense oligonucleotide and the preferred delivery mode.
  • soluble antisense oligonucleotides have been used to inhibit transcription/translation of a target gene (Ching et al , Proc. Natl. Acad. Sci. U.S.A.
  • Suitable target sequences for antisense polynucleotides include intron-exon junctions (to prevent proper splicing), regions in which DNA/RNA hybrids will prevent transport of mRNA from the nucleus to the cytoplasm, initiation factor binding sites, ribosome binding sites, and sites that interfere with ribosome progression.
  • a particularly preferred target region for antisense polynucleotides is the 5' untranslated region of the gene of interest, for example the Mena gene.
  • Antisense polynucleotides targeted to the Mena gene may also be prepared by inserting a DNA molecule containing the target DNA sequence into a suitable expression vector such that the DNA molecule is inserted downstream of a promoter in a reverse orientation as compared to the gene itself.
  • the expression vector may then be transduced, transformed or transfected into a suitable cell resulting in the expression of antisense polynucleotides.
  • antisense oligonucleotides may be synthesized using standard manual or automated synthesis techniques. Synthesized oligonucleotides may be introduced into suitable cells by a variety of means including electroporation (e.g., as described in Yang et al.. Nucl. Acids. Res. 23:2803-2810.
  • antisense oligonucleotide administration method will be evident to one skilled in the art.
  • Stabilizing agents include intercalating agents that are covalently attached to either or both ends of the oligonucleotide.
  • Oligonucleotides may be made resistant to nucleases by, for example, modifications to the phosphodiester backbone by the introduction of phosphotriesters, phosphonates, phosphorothioates, phosphoroselenoates, phosphoramidates or phosphorodithioates. Oligonucleotides may also be made nuclease resistant by the synthesis of the oligonucleotides with alpha-anomers of the deoxyribonucleotides, as generally described in Mol and Van der Krul, supra.
  • polynucleotide-based inhibitors of the present invention include the triplex forming oligonucleotides, sequence-specific DNA binding drugs that interfere with target gene transcription.
  • Triplex-forming oligonucleotides are generally described in Maher. Bioessavs 14: 807-815, 1992: Gee et a!.. Gene 149: 109-1 14, 1994; Noonberg et al.. Gene 149. 123-126, 1994; Song et al.. Ann. NY Acad. Sci. 761 : 97-108, 1995; Westin et al., Nuc. Acids. Res. 23: 2184-2191, 1995; and Wand and Glazer, J. Biol. Chem.
  • oligonucleotides form triple helical complexes under physiological conditions on double-stranded DNA, selectively inhibiting gene transcription by physically blocking RNA polymerase or transcription factor access to the DNA template. See also, e.g., WO 95/25818; WO 95/20404; WO 94/15616; WO 94/04550; and WO 93/09788, each of which is incorporated herein by reference.
  • the triplex forming oligonucleotides may contain either a nucleotide or non-nucleotide tail to enhance the inhibition of transcription factor binding.
  • the triplex forming oligonucleotides are targeted to the Mena gene.
  • the choice of a suitable sequence will be guided by, for example, the type of inhibitor (i.e., triplex forming oligonucleotide or antisense polynucleotide) and the species to be treated. It may be preferable to choose sequences that are conserved between species to permit use in readily available animal models.
  • the present invention also provides compositions and methods for using ribozyme inhibitors for inhibiting Mena expression.
  • the ribozymes can be administered in a variety of ways, including by gene therapy targeted to a desired cell.
  • a ribozyme of the invention is a targets the RNA transcripts of the gene of interest in a sequence-specific manner.
  • ribozymes may be designed to specifically inhibit the transcription of the Mena gene
  • Each ribozyme molecule is designed to contain a catalytically active segment capable of cleaving the Mena RNA, and further comprises flanking sequences having a nucleotide sequence complementary to portions of the targeted RNA.
  • the flanking sequences serve to anneal the ribozyme to the RNA in a site-specific manner.
  • Absolute complimentary of the flanking sequences to the target Mena sequence is not necessary, however, as only an amount of complimentary sufficient to form a duplex with the target RNA and to allow the catalytically active segment of the ribozyme to cleave at the target sites is necessary.
  • only sufficient complimentary to permit the ribozyme to be hybridizable with the target RNA under physiological conditions is required.
  • ribozyme means an RNA molecule having an enzymatic activity that is able to cleave or splice other separate RNA molecules in a nucleotide base sequence specific manner.
  • catalytic or enzymatic RNA molecule is meant an RNA molecule which has complementarity in a substrate binding region to a specific RNA target (e.g. Mena RNA), and also has enzymatic activity that is active to cleave and/or splice RNA in that target, thereby altering the target molecule.
  • the enzymatic RNA molecule is formed in a hammerhead motif, but the ribozyme may also be formed in the motif of a hairpin, hepatitis delta virus, group I intron or RNAse P RNA (in association with an RNA guide sequence).
  • hammerhead motifs are described by Rossi et al., AIDS Res. Hum. Retrovir. 8: 183 (1992)
  • hairpin motifs are described by Hampel et al., Biochem. 28:4929 (1989) and Hampel et al., Nucl. Acids Res. 18: 299 (1990)
  • the hepatitis delta virus motif is exemplified in Perrotta and Been, Biochem.
  • RNAseP motif is described in Guerrier-Takada et al., CeJ] 35: 849 (1983), and examples of the group I intron motif are described in Cech et al., U.S.
  • an enzymatic RNA molecule of the invention has a specific substrate binding site which is complementary to one or more of the target RNA regions and that it has nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule.
  • the flanking sequences upstream and downstream of the ribozyme catalytic site may comprise segments of any length that effectively imparts the desired degree of targeting specificity for the ribozyme.
  • flanking sequence comprises from about 4 to about 24 nucleotides, more preferably from about 6 to about 15 nucleotides, and typically about 9 to 12 nucleotides, and results in base pairing to the substrate sequence immediately upstream and downstream of the RNA sequences which comprise the cleavage site.
  • the Mena or Evl modulating agents, including Mena and Evl inhibitors and agonists, of the present invention may be used in a variety of therapeutic contexts, alone or in combination, and may be formulated for a variety of modes of administration.
  • Administration of the inhibitor or agonist may include systemic, topical or local administration. Techniques and formulations are generally described in Remington's Pharmaceutical Sciences. Mack Publishing Co., Easton, PA, latest edition.
  • the inhibitor or agonist is generally combined with a pharmaceutically acceptable carrier such as a diluent or excipient.
  • Suitable carriers may include fillers, extenders, binders, wetting agents, disintegrants, surface-active agents or lubricants. The choice of such ingredients will depend on the mode of administration and dosage forms.
  • Typical dosage forms include tablets, powders, liquid preparation including suspensions, emulsions, and solutions, granules, capsules and suppositories.
  • Liquid preparation for injection are also typical and include iiposome preparations.
  • Polynucleotide inhibitors e.g., triplex forming oligonucleotides, antisense oligonucleotide, ribozyme, etc., or a combination of such inhibitors targeted to different portions of the target DNA or corresponding RNA can be delivered in a wide variety of ways to targeted cells to facilitate inhibition of the gene of interest.
  • multiple polynucleotide inhibitors oTMena are combined and delivered to target cells to decrease the expression of Mena, thus reducing the recruitment of Mena to, for example, focal adhesions.
  • the oligonucleotides can be administered as synthetic oligonucleotides or expressed from an expression vector.
  • the oligonucleotide can be administered ex vivo, i.e., contacted with target cells that have been removed from an individual or other cell source, treated and returned, or the oligonucleotide molecule can be administered in vivo.
  • a carrier provides a means to accumulate the inhibitor or agonist within or at a desired cell population.
  • the delivery vehicle can be designed to serve as a slow release reservoir or to deliver its contents directly to the target cell.
  • oligonucleotide delivery vehicles include liposomes, hydrogels, cyclodextrins, biodegradable nanocapsules, and microspheres. Liposomes can readily be targeted to the various tissues or cell populations
  • routes of administration for Mena or Evl inhibitors and agonists include intramuscular, aerosol, intravenous, parenteral, intraperitoneal, etc
  • the specific delivery route for a selected inhibitor or agonist will depend on a variety of factors, such as the form of the inhibitor or agonist, the intended target, the condition being treated, etc.
  • oligonucleotide While unmodified oligonucleotide is taken up by cells, modifications can be made to enhance cellular uptake, e.g., by reducing the oligonucleotide's charge to produce a molecule which is able to diffuse across the cell membrane.
  • modifications can be made to enhance cellular uptake, e.g., by reducing the oligonucleotide's charge to produce a molecule which is able to diffuse across the cell membrane.
  • the structural requirements necessary to maintain oligonucleotide activity and activity of other classes of inhibitors or agonists are generally recognized in the art.
  • Modifications to enhance cellular delivery can also be designed to reduce susceptibility to nuclease digestion or other types of degradation
  • the dosage of inhibitor or agonist will also depend on a variety of factors, such as the form of the inhibitor or agonist, the route of administration, etc., and thus can vary widely Generally the dosage of inhibitors will result in inhibition oTMena activity or levels to a sufficient extent within the targeted cells sufficient to prevent formation of Mena complexes with its binding partners.
  • Establishment of effective levels of inhibitor within a targeted cell population depends upon, e g., the rate of uptake (or expression by a particular vector), and rate at which the inhibitor is degraded.
  • the duration of treatment may extend for a time sufficient to permit, e.g., transduction of a relatively high percentage of dividing cells compared to an untreated control cell population, but usually will be at least for about 2-4 days, sometimes 6-10 days, although longer durations may be necessary for quiescent or terminally differentiated cell populations.
  • the number and timing of doses can vary considerably, depending on the factors discussed above and the efficacy of a particular inhibitor or mixture thereof, the delivery vehicle and route of administration, etc.
  • oligonucleotide inhibitors of the present invention for example Mena antisense oligonucleotide inhibitors or Mena-specific triplex forming oligonucleotides, it may be preferable in include an effective concentration of a lipid formulation with the oligonucleotide. Suitable lipid formulations and concentrations are those that enhance the uptake of the oligonucleotides by cells. Such lipids include cationic lipids used for lipofection such as N- [l-(2,3-dioleyloxy)propyl-N,N,N-trimethylammonium chloride (DOTMA) and dioleoyl phophatidylethanolamine (DOPE).
  • DOTMA N- [l-(2,3-dioleyloxy)propyl-N,N,N-trimethylammonium chloride
  • DOPE dioleoyl phophatidylethanolamine
  • Mena or Evl inhibitors or agonists may be used in combination with other compounds that are useful, for example in chemotherapy or as antibiotics. These compounds include standard chemotherapeutic agents such as platin compounds (e.g. cisplatin) and antibiotics such as penicillin, tetracycline or antiviral agents such as protease inhibitors and the like.
  • platin compounds e.g. cisplatin
  • antibiotics such as penicillin, tetracycline or antiviral agents such as protease inhibitors and the like.
  • the Mena or Evl based polynucleotide expression constructs disclosed herein are employed in methods for modulating the expression oTMena or Evl, disrupting Mena or Evl expression or inducing ectopic expression oTMena or Evl genes and related polynucleotide sequences in the context of gene therapeutic methods involving mammalian host cells.
  • Mena is ectopically expressed or over expressed in mammalian cells to induce cytoskeletal changes, including for example formation of dense F-actin clusters, cell surface protrusions characterized by Mena-actin core structures, and filopodial extension and cytoplasmic bridge formation between neighboring cells.
  • a suitable gene therapy vector delivery system e.g., a retroviral vector
  • a microinjection technique see, for example, Tarn, Basic Life Sciences 37: 187-194, 1986, which is incorporated by reference herein in its entirety
  • a transfection method e.g., naked or liposome encapsulated DNA or RNA
  • a suitable gene therapy vector delivery system e.g., a retroviral vector
  • a microinjection technique see, for example, Tarn, Basic Life Sciences 37: 187-194, 1986, which is incorporated by reference herein in its entirety
  • a transfection method e.g., naked or liposome encapsulated DNA or RNA
  • a transfection method e.g., naked or liposome encapsulated DNA or RNA
  • Gene transfer vectors e.g., retroviral vectors, and the like
  • Gene therapy may be used to correct traumatic neural injury that has resulted in loss of motor or sensory neural function.
  • the introduction method may be chosen to achieve a transient expression of Mena in the host cell, or it may be preferable to achieve constitutive, tissue specific, or inducible expression.
  • Methods of treatment employing transformed host cells of the present invention are useful in a variety of in vivo settings, for example, for transplantation at sites of traumatic neural injury where motor or sensory neural activity has been lost.
  • the polynucleotide constructs and insert sequences of the invention provide the possibility of specific gene therapy for the treatment of certain neurological disorders such as Alzheimer's disease, Huntington's disease, and Parkinson's disease, in which a population of neurons have been damaged.
  • Representative patient populations that may benefit from transplantation include, but are not limited to, patients with hearing or vision loss due to optical or auditory nerve damage, patients with peripheral nerve damage and loss or motor or sensory neural function, individuals with diseases such as cancer or developmental defects relating to aberrant cytoskeletal dynamic function, and patients with brain or spinal cord damage from traumatic injury.
  • donor cells for a patient having CML are obtained from a normal stem cell population in the same patient or in a donor patient and are then transformed or transduced with a mutant Mena or Evl nucleotide sequence.
  • a preferred Mena mutant in this context can be designed to express a hyperfunctional EVH 1 domain that has a strongly enhanced binding affinity for ligands such as zyxin or vinculin that mediate Mena function in cytoskeletal dynamic processes.
  • a second mutation can be introduced in a separate functional domain, for example the proline rich, profilin binding domain, that renders the double mutant protein incapable of binding profilin to promote actin polymerization, while it remains tightly bound to its EVHl domain ligands and thereby prevents or impairs binding and function of endogenous Mena in the donor cells.
  • the transformed cells that are rendered resistant to the motility defects and loss of contact inhibition of CML cells are then returned to the patient, for example in the manner routinely performed during bone marrow transplants.
  • gene transfer may be achieved by introducing the sequences of the present invention directly to the site of the traumatic injury.
  • Example 1 Cloning of Mena and Evl A cDNA encoding Mena was identified by screening a cDNA library made from mouse embryonic stem cells (Chen et al., Proc. Natl. Acad. Sci. USA 92: 7819-7823, 1994). Filter lifts of the library were prepared on nylon membranes (HYBOND, Amersham, Arlington Heights, IL). Library screening, subcloning and polymerase chain reactions were performed, and standard solutions prepared essentially as described by Sambrook et al. (Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY, 1989, which is incorporated herein by reference in its entirety).
  • the library was screened with a 3 P-labeled (Amersham, Arlington Heights, IL) Eco Rl/Sph I fragment containing the first 106 codons of Ena (Gertler et al,, Genes Dev. 9: 521-533, 1995).
  • the filters were hybridized in a buffer containing: 1.5 x SSPE, 7% SDS, 10% PEG8000 and lxlO 6 cpm/ml of the ⁇ 2 P-labeled Ena probe overnight at 42°C.
  • the filters were washed repeatedly at 42°C in a buffer containing 2 x SSC, 1% SDS followed by washes at 60°C in a buffer containing 0.5 x SSC, 1% SDS.
  • phage Positive phage were identified by autoradiography and purified.
  • the cDNA inserts were subcloned into pBSKSII (Stratagene Cloning Systems, La Jolla, CA). The inserts were prepared and sequenced on both strands using an Applied Biosystems DNA Sequencer model 373A (Applied Biosystems, Foster City, CA) according to the manufacturer's guidelines. Analysis of overlapping cDNAs indicated that these sequences contained an open reading frame with a predicted amino acid sequence of 541 amino acids (SEQ ID NO: 1 and SEQ ID NO: 2). The complete cDNA was termed Mammalian Ena (Mena). Sequence analysis was carried out using the Genetics Computer Group software package (Devereaux et al., Nuc. Acids Res.
  • VASP Human EST accession #T80305 (obtained from , Washington University-Merck EST Project IMAGE Consortium, LLNL).
  • the EST was used to screen the library as described above.
  • a murine cDNA was isolated and sequenced as previously described in detail
  • the cDNA (nucleotide sequence and deduced amino acid sequence in SEQ ID NO:7 and SEQ ID NO: 8) was predicted to encode a 393 amino acid protein. Based on sequence analysis the cDNA was termed Ena- VASP Like (Evl).
  • Evl contains the amino-terminal site only, while Ena lacks both sites.
  • the sequence GPPPPP (SEQ ID NO: 13), which mediates binding of VASP to the actin- monomer sequestering protein profilin (Reinhard et al., EMBO J. 14: 1583-1589, 1995) is present twice in Mena and once in Evl.
  • the carboxy terminal homology domain (EVH2, spanning amino acids 507-733 in the consensus line), contains a putative G-actin binding sequence, and a conserved charge cluster.
  • the extended helical structure predicted for this repeat may function as a protein-binding interface, or serve to separate the EVHl domain from the proline-rich core of Mena
  • Both the EVH2 and the LERER (SEQ ID NO: 10) repeats were predicted to form coiled-coiled domains, structures that are implicated in protein:protein interactions, by the PEPCOIL program, which employs the predictive criteria proposed by Lupas and colleagues (Lupas et al, Science 252: 1 162-1 164, 1991, which is incorporated herein by reference in its entirety).
  • the Mena cDNA was used to probe the Jackson backcross hybrid mapping panel (The Jacson Laboratory, Bar Harbor, ME) to determine the chromosomal location of the Mena gene. Mena was localized to the mouse chromosome 1 a offset 73 which is syntenic to a human chromosomal position 1Q2I-23 (Stanier et al., Genomics 26: 473-478, 1995).
  • Mena-specific antibodies were developed. DNA fragments encoding amino acids 6-170 of SEQ ID NO: 2 (N-Mena) or amino acids 440- 537 of SEQ ID NO: 2 (C-Mena) were amplified from the Mena cDNA using polymerase chain reaction amplification. The fragments were each cloned into pGex2T (Smith and Johnson Gene 67: 31-40, 1988, which is incorporated herein by reference in its entirety) and transformed into a bacterial host to permit the expression of Mena-glutathione S- transferase fusion proteins.
  • pGex2T Smith and Johnson Gene 67: 31-40, 1988, which is incorporated herein by reference in its entirety
  • the fusion proteins were purified on a glutathione-coupled beaded agarose matrix (Glutathione SEPHAROSE, Pharmacia Biotech, Inc., Piscataway, NJ) according to the manufacturer's instructions. Rabbits were immunized and boosted with the Mena fusion proteins, and sera collected as described by Harlow and Lane in Antibodies A Laboratory Manual (Cold Spring Harbor, NY, Cold Spring Harbor Press 1988), which is incorporated herein by reference in its entirety. Affinity purified antisera raised against the peptide LKEELIDAIRQELSKSNTA (SEQ ID NO: 1 1) were produced by Quality Controlled Biochemicals, Inc. (Hopkins, MA). Purified platelet VASP protein was not recognized by any of the Mena antibodies tested.
  • Glutathione SEPHAROSE Pharmacia Biotech, Inc., Piscataway, NJ
  • Example 3 Distribution of Mena The distribution of Mena protein isoforms during a portion of mouse embryogenesis was determined by Western blot analyses of protein from dissected heads or bodies of embryo-lysates taken from stages E10 to El 5 or from Iysates of whole E9 embryos. Protein extracts were from cells or dissected embryos were prepared in ice cold R1PA buffer (25 mM Tris (pH 7.5), 150 mM NaCI, 1 % NP40, 0.5% Deoxycholate, 0.1% SDS) + 1 mM PMSF, Aprotinin and ImM NaVO . Proteins were quantified using the Pierce protein assay kit (Pierce Chemical Company, Rockford, IL).
  • Immunoprecipitations were performed with 1ml of Img/ml of head lysate using 5 ⁇ l of Anti-N-Mena (from rabbit 2188) or 2188 pre-immune sera. Fifty micrograms of protein were used for Western blotting of total cell Iysates. Gel elect rophoreses and Western blotting on polyvinylidene fluoride membranes (PVDF, Millipore, Bedford, MA) were performed as described by Harlow and Lane (ibid.) and according to the manufacturer's instructions. Signals were visualized using chemiluminescence (Dupont Co. (NEN Life Science Products), Wilmington, DE).
  • the 140 kD band was also enriched during the course of retinoic acid-induced differentiation of the P19 embryonic carcinomal stem cells into neurons (Rudnicki and McBurney, Cell Culture Methods and Induction of Differentiation of Embryonal Carcinoma Cell Lines. In Teratocarcinomas and Embryonic Stem Cells: A Practical Approach. E. Robertson, ed., Oxford, England, pp. 19-47, 1987; which is incorporated herein by reference in its entirety).
  • Anti-Mena Western blot analyses of Iysates from P19 embryonic carcinomal cells at 0,3,5, and 7 days after treatment with retinoic acid demonstrated that the 140 kD form of Mena was induced during the differentiation process.
  • the translation products were subjected to gel electrophoresis, and the gels were fixed and treated with Amplify (Amersham, Arlington Heights, IL). The fixed gels were dried and quantified using a phosphoimager (Molecular Dynamics, Sunnyvale, CA). Translation of the Mena cDNA gave rise to a protein that co- migrates with the 80 kD band, while expression of the neural Mena cDNA (Example 4) in fibroblasts produced a signal at 140 kD in addition to the endogenous doublet at 80 kD. These data indicate that the 80 kD signal is a broadly expressed form of Mena, while the 140 kD signal is a Mena isoform enriched in, or specific to neural cell types and produced by alternative splicing. The 88 kD signal is immunoreactive with all anti-Mena antibodies tested, and may represents another splice variant, or a post-translationally modified form of Mena.
  • Neural Mena * contained an exon that introduces 244 amino acids (corresponding to amino acid 239 through amino acid 482 of SEQ ID NO: 4) between amino acids 238 and 239 of (SEQ ID NO: 2).
  • the nucleotide sequence and deduced amino acid sequences of neural Mena are shown in (SEQ ID NO: 3 and SEQ ID NO:4).
  • Two other isoforms, neural Mena ** and neural Mena +++ contained the exon insertion described for Neural Mena * and either a exon insertion between amino acids 1 16 and 1 17 of SEQ ID NO: 2.
  • the deduced amino acid sequences of neural Mena ** and neural Mena *** are shown in SEQ ID NO: 5 and SEQ ID NO:6, respectively.
  • Mena immunoprecipitation The presence of potential phosphorylation sites in the deduced amino acid sequence of Mena and the phosphorylation that has been demonstrated on VASP and Ena suggests that Mena is phosphorylated.
  • the phosphorylation status of Mena was determined by immunoprecipitation.
  • RIP A Iysates from E12 embryonic heads were immunoprecipitated using anti-N terminal Mena antibodies or pre-immune sera . The precipitates were analyzed by Western blotting as described above with the 4G10 anti- phosphotyrosine monoclonal antibody.
  • Mena immunoprecipitates from El 2 head Iysates contained an anti-phosphotyrosine reactive signal that co-migrates with the 140 kD form.
  • the 80 and 88 kD forms contained no detectable phosphotyrosine.
  • Mena expression was examined in the rat embryo line Rat2 (ATCC CRL 1764). The cells were grown in Dulbecco's Modified Eagle's Medium (DMEM; Life Technologies (GIBCO/BRL), Gaithersburg, MD) supplemented with 10% FCS. In Rat2 cells, Mena migrates as an 80 kD doublet. Treatment of Mena protein with purified protein kinase A (New England Biolabs, Beverly, MA) according the manufacturer's instructions caused a quantitative conversion of the 80 kD form of Mena to the slower migrating form of the doublet.
  • DMEM Dulbecco's Modified Eagle's Medium
  • Rat2 cells Mena migrates as an 80 kD doublet. Treatment of Mena protein with purified protein kinase A (New England Biolabs, Beverly, MA) according the manufacturer's instructions caused a quantitative conversion of the 80 kD form of Mena to the slower migrating form of the doublet.
  • the Mena cDNA was translated in vitro and labeled with 35 S-methionine as described previously.
  • the translation product migrated as an 80 kD doublet.
  • Addition of protein kinase A shifted the mobility of the lower band to that of the upper, indicating that this doublet was caused by partial serine phosphorylation in the lysate.
  • Rat2 cells were grown in DMEM (Life Technologies (GIBCO BRL), Gaithersburg, MD) supplemented with 10% FCS on glass coverslips coated with 5 ⁇ g/cm 2 fibronectm (Sigma Biosciences, St. Louis, MO). Cells were fixed with either 3% or ice-cold 4% paraformaldehyde in phosphate buffered saline (PBS) for 10 minutes. The fixed cells were permeabilized with 0.2% (v/v) Triton X-100 in PBS and stained as described (Harlow and Lane, ibid.). Mena-specific antisera was used at dilution of 1 :400.
  • FITC Fluorescein
  • Texas Red secondary antibody conjugates were purchased from Jackson Immunoresearch Laboratories, Inc., West Grove, PA) and used at a dilution of 1 : 100.
  • Phosphotyrosine and neurofilaments detected using mab4G10 were purchased from Jackson Immunoresearch Laboratories, Inc., West Grove, PA.
  • Bodipy phalloidin (Molecular Probes Inc., Eugene, OR) was used to stain F-actin, DAPI (Sigma, St. Louis, MO) was used to stain nuclei, and Vectashield mounting media (Vector Labs, Burlingame, CA) were used to in the preparation of the images. Three dimensional microscopic images were captured and processed using a Deltavision microscope and software (Applied Precision Inc., Mercer Island, WA).
  • Mena was restricted to the proximal portions of the phosphotyrosine domain in most focal contacts, at the ends of F-actin stress fibers. Therefore, Mena distribution overlaps with molecules that are receiving extracellular matrix-induced signals and with regions of microfilament assembly.
  • the EVHl domain was used to purify proteins from embryo cell Iysates.
  • N-Mena-Gst the Gst-fusion protein containing amino acids 6-170 of Mena (described in Example 2) encompasses the EVHl domain.
  • Five micrograms of N- Mena-Gst or Gst alone was immobilized on a glutathione-coupled beaded agarose matrix (Glutathione SEPH AROSE, Pharmacia Biotech, Inc., Piscataway, NJ) according to the manufacturer's instructions.
  • the N-Mena matrix was mixed with 1ml of lmg/mi of RIPA Iysates of E12 heads, or human erythrocytic leukemia cells (HEL) (described above) and incubated overnight at 4°C. Samples were washed three times in RIPA, and bound proteins analyzed by Western blot analysis with antibodies to zyxin (obtained from Dr. Mary Beckerle University of Utah), vinculin or the Ack kinase (Santa Cruz Biotechnology Inc., Santa Cruz, CA), which contains a similar proline-rich motif. The antibodies were used at a 1 : 100 dilution.
  • N-Mena matrix retained more than 50% of the total endogenous zyxin, and detectable amounts of vinculin. Ack was not recovered detectably, indicating that the motif in Ack lacks some feature critical for binding in vivo, or that the sequence is not accessible. These results indicate that N-Mena is capable of binding to zyxin and vinculin.
  • potoroo kidney epithelial cells (ATCC CCL 56) were seeded in Modified Essential Medium (MEM; Life Technologies (GIBCO/BRL), Gaithersburg, MD) supplemented with 10% FCS, glutamine and non- essential amino acids to semi confluency onto CELLocate coverslips (Eppendorf, Hamburg, Germany) two days prior to microinjection.
  • MEM Modified Essential Medium
  • FCS FCS
  • glutamine glutamine
  • non- essential amino acids to semi confluency onto CELLocate coverslips
  • MES- buffer 0.1 M MES, 4 % PEG 6000 (w/v), 1 mM MgCl (pH 7.6)
  • MES-buffer 0.2% Triton X-100
  • cells were fixed with paraformaldehyde, and then incubated 30 minutes each with primary and fluorescently labeled secondary antibodies and phalloidin.
  • Microinjected Gst-N terminal Mena fusion protein was detected using polyclonal anti-GST antibodies.
  • Fluorescence photomicroscopy was carried out on a Zeiss Axiophot with appropriate filter sets for epifluorescence detection of FITC and rhodamine signals.
  • the microinjection of N-Mena-Gst fusion protein into PtK 2 cells demonstrated that the N- Mena sequences directed the fusion protein to focal adhesions.
  • Gst alone was injected, diffuse signal was observed throughout the cell.
  • a peptide corresponding to amino acids 293-312 of the ActA sequence was also injected into PtK 2 cells.
  • the ActA peptide (SEQ ID NO.12) was first coupled to ovalbumin as described previously (Pistor et al., Curr. Biol.5: 517-525, 1995; which is incorporated herein by reference in its entirety), and the conjugate was microinjected along with rhodamine-coupled BSA as a marker protein. The cells were then returned to the incubator for 15 to 30 minutes before fixation.
  • a retroviral vector was used to drive increased levels, or ectopic expression of the different Mena isoforms in Rat2 cells.
  • Rat2 cells were grown under conditions described previously.
  • Retroviruses were constructed by inserting full length Mena cDNAs (Mena, neural Mena, Isoform 1 or Isoform 2) into the pBABE vector (Morgenstern and Land, Nuc. Acids Res. 18: 3587-3596, 1990, which is incorporated herein by reference in its entirety), packaged and used to infect fibroblasts as described Morgenstern and Land (ibid.).
  • Mena and F-actin were immunostained to determine the distribution of Mena and F-actin three days after infection with the parental virus or viruses programmed to express the various Mena isoforms.
  • Expression of the 80 kD form of Mena caused the formation of localized clusters of Mena and F-actin. More dramatic results were observed when any of the three neural variants of Mena were used. The over-expression of neural Mena was particularly dramatic.
  • individual cells in the experimental population expressed varying degrees of neural Mena as judged by fluorescence intensity. Similar increases in Mena immunofiuorescence intensity across the population were observed with the 80 kD form, or any of the three neural Mena variants.
  • An optical section taken at the plane of cell-substratum contact showed a relatively normal distribution of Mena, mainly in focal contacts and at the cell periphery, and F-actin, mainly in typical stress fibers.
  • An optical section taken 3.8 ⁇ M above the substratum contact indicated the Mena-induced projections extend above the top of the nuclei.
  • Comparison of the Mena and F-actin staining at this level indicated that Mena is distributed at the periphery of the F-actin, potentially at the site of F-actin polymerization and nucleation in these projections.
  • Mena The ability of Mena to interact with SH3 and profilin binding was determined by using assays were described by Reinhard et al.(ibid., 1995) and Weng et al. (J. Biol. Chem. 268: 14956-14963, 1993), which are incorporated herein by reference in their entirety). Mena protein was labeled with 35 S-methionine by in vitro using the TNT coupled transcription/translation system (Promega Corp, Madison, CA) according to the manufacturer's instruction.
  • profilin was coupled to a NHS-activated agarose matrix (NHS -activated HiTrap-column, Pharmacia Biotech, Inc., Piscataway, NJ) following the manufacturer's instructions. Chromatography steps were carried out at 4°C. Radiolabeled Mena protein was loaded onto the column in the presence or absence of 1 mg/ml GPPPPP (SEQ ID NO: 13). Proteins were eluted from the column with buffer B (50 mM Tris-HCl (pH 7.2), 1 mM DTE, 5 mM MgCI 2 , 150 mM NaCI, 0.1% BSA) with 5 mg/ml poly-L-proline (1-10 kD, Sigma, St. Louis, MO).
  • buffer B 50 mM Tris-HCl (pH 7.2), 1 mM DTE, 5 mM MgCI 2 , 150 mM NaCI, 0.1% BSA
  • the eluates were analyzed by SDS-PAGE and autoradiography. Autoradiography demonstrated that 83% of the input Mena was retained on the profilin-SEPHAROSE column as determined by phosphoimager analysis of the gel. Equal binding of the phospho- and dephospho forms of Mena was observed. In the presence of the competitor peptide, the amount of Mena retained was reduced to 13%.
  • Mena-profilin binding was also assessed by incubating 5 x 10 15 M of Mena with increasing concentrations of profilin to determine the % of Mena bound.
  • the profilin-SEPHAROSE matrix was diluted with Sepharose to create columns bound with known, increasing profilin concentrations.
  • the 5 x 10 I5 M of in vitro translated, radiolabeled Mena was mixed with profilin-Sepharose matrix and unbound Mena was washed from the column.
  • the bound Mena was quantified by scintillation analysis. This analysis demonstrated that the Mena binding is saturable.
  • Gst-AblSH3, GstScrSH3 (described by Gertler et al., ibid., 1995; which is incorporated herein by reference in its entirety).
  • the Gst fusions proteins were each bound to glutathione-SEPHAROSE as described previously.
  • the SH3-SEPHAROSE matrix was then gel electrophoresis and autoradiography. Gst alone was used as a control, and as expected, no binding to Gst was observed.
  • the AblSH3 retained 21% and 1 % of the input dephospho-, or Phosphorylated input Mena, respectively.
  • the SrcSH3 retained 8% and 3% of the dephospho-, or phosphorylated Mena, respectively. In both cases, the dephosphorylated form of Mena was more efficiently purified from the lysate.
  • the Gst-SH3 fusion proteins were also used to purify Mena from RIPA head Iysates.
  • the Gst-fiision proteins were each bound to the glutathione-SEPHAROSE matrix as described above.
  • RIPA head Iysates were added to the matrix.
  • the matrix was washed, and the bound protein was eluted and analyzed.
  • both the broadly distributed and neural Mena forms were purified.
  • Mena is involved in the microfilament assembly required for Listeria motility
  • L. monocytogenes serotype l/2a EGD were grown in brain-heart infusion (BHI) broth (DIFCO Laboratories, Inc., Detroit, MI) at 37°C with aeration.
  • BHI brain-heart infusion
  • PtK 2 cells were grown on coverslips, and bacteria from an overnight culture were added directly to the culture medium at a dilution of 1 :200. After 1-2 hours the plates were extensively washed with fresh medium containing 25 ⁇ g/ml gentamicin to kill extracellular bacteria.
  • Knock-out mice in which the murine Mena coding sequence was replaced with the ⁇ -galactosidase gene and the neomycin resistance gene (neo) were generated i) to assess the consequences of eliminating the murine Mena protein during mouse development ii) to permit examination of the expression pattern oTMena in embryonic mice iii) to generate Mena * cell lines and iv) to cross the mice with mice carrying onco-genes to study the effects of such double mutants.
  • Genomic Mena sequences used for these knock-out mice were obtained from the 129/Sv mice so t the homologous recombination could take place in a congenic background in 129/Sv mouse embryonic stem cells.
  • Mena genomic clones were isolated from a genomic library prepared from 129/Sv mice (Zhuang et al., £eJJ 79: 875-884, 1994; which is incorporated herein by reference in its entirety) using a random- primed Mena cDNA probe.
  • Plasmid pSA ⁇ Geolox2DTA contains the ⁇ - galactosidase/neomycin resistance gene fusion ( ⁇ Geo) and the Diptheria toxin gene under the control of the PGK promoter in a pBLUESCRIPT (Stratagene Cloning Systems, La Jolla, CA) vector backbone was used to create the targeting construct.
  • a 10 kb 5' Mena genomic fragment, the 4 kb cytoplasmic ⁇ Geo gene and the 1 kb fragment containing the genomic 3' untranslated sequence of Mena was inserted 5' of the Diptheria toxin expression cassette in the pSA ⁇ Geolox2DTA vector backbone.
  • the targeting construct was linearized at a unique restriction site in the vector backbone and was transfected by electroporation into mouse embryonic stem (ES) cells.
  • ES mouse embryonic stem
  • a 129/Sv derived ES cell line, AK-7 described by Zhuang et al. (ibid.) was used for electroporation.
  • ES cells were routinely cultured on mitomycin C-treated (Sigma) SNL 76/7 cells (feeder cells) as described by McMahon and Bradley (Cell 62: 1073-1085, 1990; which is incorporated herein by reference in its entirety) in culture medium containing high glucose DMEM supplemented with 15% fetal bovine serum (Hyclone) and 0.1 ⁇ M (micromolar) ⁇ -mercaptoethanol.
  • Hyclone fetal bovine serum
  • 25 g (micrograms) of the targeting construct was linearized by digestion with Not I, phenol-chloroform extracted, and ethanol precipitated. The linearized vector was then electroporated into 1-2 x 10 7 AK-7 (ES)cells.
  • the electroporated cells were seeded onto three 10-cm plates with one plate receiving 50% of the electroporated cells and the remaining two plates each receiving 25% of the electroporated cells.
  • G418 was added to each of the plates to a final concentration of 300 ⁇ g/ml (micrograms per milliliter).
  • the culture medium for each plate was changed every day for the first few days, and then changed as needed after selection had occurred. After 10 days of selection, a portion of each colony was picked microscopically with a drawn micropipette, and was directly analyzed by PCR as described by Joyner et al. (Nature 338: 153-156, 1989; which is incorporated herein by reference in its entirety).
  • PCR amplification was performed as described (Kogan et al., New England J. Med. 317: 985-990, 1987; which is incorporated herein by reference in its entirety) using 40 cycles of 93°C for 30 seconds, 57°C for 30 seconds, and 65°C for 3 minutes.
  • primers MF and MR SEQ ID NOS: 14 and 15, respectively
  • primers BPAF and MR SEQ ID NOs: 16 and 15, respectively
  • each positive clone was thawed and passaged once on feeder cells.
  • the transfected cells were trypsinized into single cells, and blastocysts obtained from C57BL/6J mice were injected with approximately 15 cells.
  • the injected blastocysts were then implanted into pseudopregnant mice (C57BL/6J x CBA).
  • Six male chimeras arose from the injected blastocysts. All of the male chimeras gave germ-line transmission at a high rate as determined by the frequency of agouti coat color transmission to their offspring (FI) in a cross with C57BL/6J female mice.
  • FI agouti coat color offspring
  • chimeric mice or FI heterozygous progeny from the chimera x C57B/6J mating were crossed with C57B/6J. Litters resulting from these crosses were harvested from pregnant females and stained for ⁇ -galactosidase activity. The embryos were dissected away from all the extra-embryonic tissue and the yolk sac was reserved for DNA analysis. The embryos were fixed for one hour in a Fix solution containing (0.1 M phosphate buffer containing 0.2% glutaraldehyde, 2% formaldehyde, 5 mM EGTA (pH 7.3), 2 mM MgCl2).
  • the fixing solution was removed by three thirty-minute rinses with rinse solution (0.1 M phosphate buffer (pH 7.3) containing 2 mM MgCl2, 0.1% sodium deoxycholate, 0.2% NP-40).
  • rinse solution 0.1 M phosphate buffer (pH 7.3) containing 2 mM MgCl2, 0.1% sodium deoxycholate, 0.2% NP-40.
  • the fixed embryos were stained overnight in the dark in rinse solution containing 1 mg/ml X-gal, 5 mM sodium ferricyanide, 5 mM sodium ferrocyanide. After staining, the embryos were rinsed with PBS and stored in the Fix solution before preparation for examination. Examination of stained tissue from fetal and postnatal mice heterozygous for the mutation demonstrated Mena expression pattern in the nervous system, somites, muscle tissue, neural crest cells and in the gut.
  • IMMORTOMOUSE is a mouse carrying a H-2Kb-tsA58 SV40 large T antigen transgene.
  • the progeny of the cross were subjected to PCR analysis as generally described above to identify progeny carrying the transgene and are heterozygous for the Mena knock out gene.
  • the progeny carrying both the transgene and the Mena knock out gene were back-crossed to the Mena " heterozygotes.
  • the progeny of the back-cross were subjected to PCR analysis to identify homozygous Mena ' progeny carrying the transgene.
  • Cells from the resulting mice may be immortalized by culturing the cells at 33°C in the presence of interferon.
  • ORGANISM Mus musculus
  • ORGANISM Mus musculus
  • ACAGACTTTC CACCAATGGA GGGATGCTAG ACAGGTGTAT GGTCTCAACT TTGGCAGCAA 420
  • ORGANISM Mus musculus
  • TCCCCATCCC CAGGTACCCG AGCCACCAGC CAGCCACCTA ATTCCTCAGA GGCTGGCAGA 1380

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne deux nouveaux gènes de mammifères Mammalian Ena (Mena) et Ena-VASP like (Evl) codant de nouvelles protéines, Mena et Evl. Les protéines Mena et Evl comportent un domaine fonctionnel EVH1 discret responsable de la liaison du Mena avec l'ActA du Listeria et avec les protéines de cytosquelette de la zyxine et de la vinculine. Le domaine EVH1 du Mena est également responsable du ciblage, et suffisant au ciblage, de la localisation du Mena et des protéines hybrides basées sur le Mena sur des adhésions focales et sur la surface des Listeria, sur le site polaire où est induite la formation empanachée de l'actine. On décrit plusieurs procédés et compositions basés sur les gènes et protéines Mena et Evl de la présente invention permettant de cribler, d'isoler et de caractériser des facteurs endogènes et exogènes, des médicaments et des agents thérapeutiques utiles pour l'évaluation et/ou la régulation des phénomènes dynamiques du cytosquelette intervenant dans la morphologie, l'adhésion, la motilité, la croissance et/ou la différenciation cellulaires normales et anormales.
PCT/US1997/011669 1996-07-05 1997-07-03 Procede de criblage de proteines mena intervenant dans la dynamique des microfilaments WO1998001755A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67581596A 1996-07-05 1996-07-05
US08/675,815 1996-07-05

Publications (2)

Publication Number Publication Date
WO1998001755A1 true WO1998001755A1 (fr) 1998-01-15
WO1998001755A9 WO1998001755A9 (fr) 1998-05-28

Family

ID=24712083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/011669 WO1998001755A1 (fr) 1996-07-05 1997-07-03 Procede de criblage de proteines mena intervenant dans la dynamique des microfilaments

Country Status (1)

Country Link
WO (1) WO1998001755A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001071356A2 (fr) * 2000-03-22 2001-09-27 Centre National De La Recherche Scientifique SEQUENCES PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
WO2001074858A2 (fr) * 2000-04-03 2001-10-11 Massachusetts Institute Of Technology Procedes de modification des cellules t et d'activation de macrophages
WO2001074378A2 (fr) * 2000-04-03 2001-10-11 The Regents Of The University Of California Processus permettant de favoriser la croissance des cellules par inhibition de proteines activees ou leurs ligands
WO2001074853A2 (fr) * 2000-04-03 2001-10-11 Massachusetts Institute Of Technology Methodes et produits permettant de reguler la motilite cellulaire
WO2002042777A2 (fr) * 2000-11-25 2002-05-30 Aventis Pharma Deutschland Gmbh Procedes de criblage de composes chimiques pour la modulation de l'interaction d'un domaine evh1 ou d'une proteine presentant un domaine evh1 avec un domaine de liaison de evh1 ou avec une proteine presentant un domaine de liaison de evh1, et procedes de detection de ladite interaction
WO2008097466A3 (fr) * 2007-02-02 2008-11-20 Einstein Coll Med Variantes d'épissages spécifiques métastatiques de mena, et utilisation de celles-ci dans le diagnostic, le pronostic et le traitement de tumeurs
EP2529225A1 (fr) * 2010-01-27 2012-12-05 The Albert Einstein College Of Medicine Of Yeshiva University Méthodes de détermination d'agents ciblant les isoformes de mena et utilisations associées pour le diagnostic et le traitement de tumeurs métastatiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOPHYS. J., September 1995, Vol. 69, No. 3, ODDE D.J., "Kinetics of Microtubule Catastrophe Assessed by Probabilistic Analysis", pages 796-802. *
CELL, 18 October 1996, Vol. 87, No. 2, GERTLER F.B., "Mena, a Relative of VASP and Drosophila Enabled, is Implicated in the Control of Microfilament Dynamics", pages 227-239. *
PROG. BRAIN RES., 1994, Vol. 102, BLACK M.M., "Microtubule Transport and Assembly Cooperate to Generate the Microtubule Array of Growing Axons", pages 61-77. *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2806805A1 (fr) * 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
WO2001071356A2 (fr) * 2000-03-22 2001-09-27 Centre National De La Recherche Scientifique SEQUENCES PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
WO2001071356A3 (fr) * 2000-03-22 2003-02-27 Centre Nat Rech Scient SEQUENCES PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
US6716597B2 (en) 2000-04-03 2004-04-06 Massachusetts Institute Of Technology Methods and products for regulating cell motility
WO2001074858A2 (fr) * 2000-04-03 2001-10-11 Massachusetts Institute Of Technology Procedes de modification des cellules t et d'activation de macrophages
WO2001074378A2 (fr) * 2000-04-03 2001-10-11 The Regents Of The University Of California Processus permettant de favoriser la croissance des cellules par inhibition de proteines activees ou leurs ligands
WO2001074853A2 (fr) * 2000-04-03 2001-10-11 Massachusetts Institute Of Technology Methodes et produits permettant de reguler la motilite cellulaire
WO2001074378A3 (fr) * 2000-04-03 2002-02-28 Univ California Processus permettant de favoriser la croissance des cellules par inhibition de proteines activees ou leurs ligands
WO2001074853A3 (fr) * 2000-04-03 2002-04-25 Massachusetts Inst Technology Methodes et produits permettant de reguler la motilite cellulaire
WO2001074858A3 (fr) * 2000-04-03 2002-05-30 Massachusetts Inst Technology Procedes de modification des cellules t et d'activation de macrophages
WO2002042777A2 (fr) * 2000-11-25 2002-05-30 Aventis Pharma Deutschland Gmbh Procedes de criblage de composes chimiques pour la modulation de l'interaction d'un domaine evh1 ou d'une proteine presentant un domaine evh1 avec un domaine de liaison de evh1 ou avec une proteine presentant un domaine de liaison de evh1, et procedes de detection de ladite interaction
WO2002042777A3 (fr) * 2000-11-25 2004-01-15 Aventis Pharma Gmbh Procedes de criblage de composes chimiques pour la modulation de l'interaction d'un domaine evh1 ou d'une proteine presentant un domaine evh1 avec un domaine de liaison de evh1 ou avec une proteine presentant un domaine de liaison de evh1, et procedes de detection de ladite interaction
US7563582B2 (en) 2000-11-25 2009-07-21 Sanofi-Aventis Deutschland Gmbh Process for screening chemical compounds for modulating the interaction of an EVH1 domain and a process for detecting said interaction
WO2008097466A3 (fr) * 2007-02-02 2008-11-20 Einstein Coll Med Variantes d'épissages spécifiques métastatiques de mena, et utilisation de celles-ci dans le diagnostic, le pronostic et le traitement de tumeurs
US8603738B2 (en) 2007-02-02 2013-12-10 Albert Einstein College Of Medicine Of Yeshiva University Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors
US9719142B2 (en) 2007-02-02 2017-08-01 Albert Einstein College Of Medicine, Inc. Metastasis specific splice variants of Mena and uses thereof in diagnosis, prognosis and treatment of tumors
EP2529225A1 (fr) * 2010-01-27 2012-12-05 The Albert Einstein College Of Medicine Of Yeshiva University Méthodes de détermination d'agents ciblant les isoformes de mena et utilisations associées pour le diagnostic et le traitement de tumeurs métastatiques
EP2529225A4 (fr) * 2010-01-27 2013-08-14 Einstein Coll Med Méthodes de détermination d'agents ciblant les isoformes de mena et utilisations associées pour le diagnostic et le traitement de tumeurs métastatiques

Similar Documents

Publication Publication Date Title
KR100603683B1 (ko) 활막세포 단백질
US7994294B2 (en) Nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase
Kamata et al. Isolation and characterization of a bovine neural specific protein (CRMP-2) cDNA homologous to unc-33, a C. elegans gene implicated in axonal outgrowth and guidance
JPH10513359A (ja) サイクリン依存性キナーゼＣＤＫ４およびＣＤＫ６のインヒビター、ＩｎＫ４ｃ−ｐ１８およびＩｎＫ４ｄ−ｐ１９、ならびにそれらの使用
JP2002510490A (ja) Ｌｙｓｔタンパク質複合体およびｌｙｓｔ相互作用タンパク質
US5885797A (en) Polynucleotide sequences encoding proteins involved in myogenesis
WO1998001755A1 (fr) Procede de criblage de proteines mena intervenant dans la dynamique des microfilaments
WO1998001755A9 (fr) Procede de criblage de proteines mena intervenant dans la dynamique des microfilaments
JP2006526383A (ja) 杯細胞関連疾患の診断、予防、改善、治療を行なうための方法と薬
US6987004B1 (en) Genes integrating signal transduction pathways
AU7966498A (en) Methods and compositions for treating abnormal cell growth related to unwanted guanine nucleotide exchange factor activity
US5705380A (en) Identification of a gene encoding TULP2, a retina specific protein
JP2003018992A (ja) Ｐａｅｌ受容体、Ｐａｅｌ受容体発現細胞および動物、ならびにパーキンソン病治療薬のスクリーニング法
US6723838B1 (en) Signal transducing synaptic molecules and uses thereof
WO1999002724A2 (fr) Procede d'identification de genes exprimes dans des lignees selectionnees et nouveaux genes identifies au moyen de ces procedes
JP2001504349A (ja) レセプターチロシンキナーゼ遺伝子
US5776762A (en) Obesity associated genes
WO2000011157A9 (fr) Dysferline, gene mute dans la myopathie distale et la myopathie des ceintures
US7402406B2 (en) Methods of evaluating phosphatase inhibitors
EP1227106A1 (fr) Protéines proapoptotiques et de molécules d'ADN codant ces protéines
US6673570B1 (en) Smad associating polypeptides
US5770432A (en) Obesity associated genes
US20030105001A1 (en) Pro-apoptotic proteins and DNA molecules encoding them
JPWO2002064770A1 (ja) 新規スカベンジャー受容体クラスａ蛋白質
AU775409B2 (en) Meg-3 protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1-36 AND 42-73, DESCRIPTION, REPLACED BY NEW PAGES 1-36 AND 42-83; PAGE 74, CLAIMS, REPLACED BY NEW PAGE 84; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 98505281

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载